Technical Analysis for PLRX - Pliant Therapeutics, Inc.

Grade Last Price % Change Price Change
grade B 21.54 -3.93% -0.88
PLRX closed down 3.93 percent on Friday, September 25, 2020, on 1.89 times normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A Down Down
Historical PLRX trend table...

Date Alert Name Type % Chg
180 Bearish Setup Bearish Swing Setup 0.00%
Slingshot Bearish Bearish Swing Setup 0.00%
Stochastic Buy Signal Bullish 0.00%
Calm After Storm Range Contraction 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Calm After Storm Range Contraction -3.93%
Lower Bollinger Band Walk Weakness -3.93%
New 52 Week Low Weakness -3.93%
Older End-of-Day Gignals for PLRX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Pliant's lead product candidate, PLN-74809, is an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins that it is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. PLN-74809 has received Orphan Drug Designation from the U.S. Food and Drug Administration for both IPF and PSC. Pliant is currently recruiting two Phase 2a trials of PLN-74809 for the treatment of IPF and plans to initiate a Phase 2a trial in PSC in the second half of 2020. Pliant's second product candidate, PLN-1474, is a small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis, or NASH, which Pliant has partnered with Novartis. PLN-1474 is currently undergoing a Phase 1 trial. In addition to clinical stage programs, Pliant currently has two preclinical programs targeting oncology and muscular dystrophies.
Medicine Hepatitis Hepatology Idiopathic Pulmonary Fibrosis Non Alcoholic Fatty Liver Disease Fibrosis Liver Fibrosis Primary Sclerosing Cholangitis Muscular Dystrophies

Is PLRX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 35.63
52 Week Low 20.1
Average Volume 122,347
200-Day Moving Average 0.00
50-Day Moving Average 24.92
20-Day Moving Average 24.99
10-Day Moving Average 25.02
Average True Range 2.42
ADX 21.11
+DI 19.05
-DI 20.13
Chandelier Exit (Long, 3 ATRs ) 24.67
Chandelier Exit (Short, 3 ATRs ) 27.37
Upper Bollinger Band 28.62
Lower Bollinger Band 21.35
Percent B (%b) 0.03
BandWidth 29.09
MACD Line -0.54
MACD Signal Line -0.02
MACD Histogram -0.5157
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 25.49
Resistance 3 (R3) 25.76 24.71 24.83
Resistance 2 (R2) 24.71 23.71 24.58 24.61
Resistance 1 (R1) 23.13 23.09 22.61 22.86 24.39
Pivot Point 22.08 22.08 21.82 21.95 22.08
Support 1 (S1) 20.50 21.08 19.98 20.23 18.69
Support 2 (S2) 19.45 20.46 19.32 18.47
Support 3 (S3) 17.87 19.45 18.25
Support 4 (S4) 17.60